Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
48
days
The economic impact of pediatric RSV-related lower respiratory tract infection in Germany: evidence from the PAPI study
AuthorsMoritz Wick; Oliver Damm; Rolf Kramer; Mathieu Bangert; Jessica Baehre; Frank Eberhardt; Grit Barten-Neiner; David Twardella; Mareike Meier-Maiwald; Christine Happle; Martin Wetzke
Affiliations1. Sanofi-Aventis Deutschland GmbH; 2. Sanofi Vaccines; 3. Pediatric Hospital Bult; 4. CAPNETZ Stiftung; 5. Pediatric Pneumology, Allergology, Neonatology, Hannover Medical School
52
days
Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States
AuthorsDaniel Hill-McManus; Yizhen Lai; Arielle G. Bensimon; Joshua Young; Kelly Reeve; Anjela Tzontcheva; Patrick Squires; Haojie Li; Chethan Ramamurthy; Matthew Mossanen
Affiliations1. MSD (UK) Limited; 2. Merck & Co., Inc; 3. Analysis Group, Inc; 4. MSD; 5. Brigham and Women’s Hospital
87
days
Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal – A modeling approach
AuthorsFilipa de Aragão; Ana Carneiro; Susana Carvalho; Cláudia Claudino; Eduardo Espada; Filipa Moita; Maria João Silva; Sónia Pereira; Alexandra Santos
Affiliations1. Public Health Research Centre, NOVA University of Lisbon; 2. Incremental Action Consulting, Lda; 3. Unidade Local de Saúde de São João; 4. Instituto Português de Oncologia de Lisboa; 5. Unidade Local de Saúde de Lisboa Ocidental, EPE, Hospital S. Francisco Xavier; 6. Unidade Local de Saúde Santa Maria, EPE; 7. Instituto Português de Oncologia do Porto; 8. Department of Biology, University of St. Andrews; 9. Gilead Sciences, Lda
109
days
Real-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United States
AuthorsJaromir Mikl; Tiange Yu; Xin Zhao; Catherine Allende; Amie Devlin; Valentine Pascale; Roger Dmochowski
Affiliations1. Purdue Pharma L.P; 2. Genesis Research Group; 3. Knoa Pharma LLC; 4. Department of Urology, Vanderbilt University Medical Center
103
days
Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective
AuthorsBraydon Nault; David Garcia; Heather Cameron; Andrew Revel; Kevin Steele; Kyle Flannery; Pedro Barata
Affiliations1. EVERSANA Inc; 2. Sanofi; 3. University Hospitals Seidman Cancer Center
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days